EA202092753A1 - BISPECIFIC ANTIBODIES TO BCMA / CD3 AND GPRDC5D / CD3 FOR USE IN THE TREATMENT OF CANCER - Google Patents

BISPECIFIC ANTIBODIES TO BCMA / CD3 AND GPRDC5D / CD3 FOR USE IN THE TREATMENT OF CANCER

Info

Publication number
EA202092753A1
EA202092753A1 EA202092753A EA202092753A EA202092753A1 EA 202092753 A1 EA202092753 A1 EA 202092753A1 EA 202092753 A EA202092753 A EA 202092753A EA 202092753 A EA202092753 A EA 202092753A EA 202092753 A1 EA202092753 A1 EA 202092753A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
bispecific antibodies
bcma
gprdc5d
cancer
Prior art date
Application number
EA202092753A
Other languages
Russian (ru)
Inventor
Хомер Адамс
Франсуа Годе
Крис Фрерихс
Нильс Ван Де Донк
Кристи Верклей
Original Assignee
Янссен Байотек, Инк.
Стихтинг Вюмк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк., Стихтинг Вюмк filed Critical Янссен Байотек, Инк.
Priority claimed from PCT/IB2019/054033 external-priority patent/WO2019220368A1/en
Publication of EA202092753A1 publication Critical patent/EA202092753A1/en

Links

Abstract

Настоящая заявка относится к биспецифическим антителам, либо BCMA*CD3, либо GRRC5D*CD3. Биспецифические антитела предназначены для применения в лечении рефрактерных раковых заболеваний, особенно после предшествующего лечения антителом к CD38.This application relates to bispecific antibodies, either BCMA * CD3 or GRRC5D * CD3. Bispecific antibodies are intended for use in the treatment of refractory cancers, especially after prior treatment with an anti-CD38 antibody.

EA202092753A 2019-05-02 2019-05-15 BISPECIFIC ANTIBODIES TO BCMA / CD3 AND GPRDC5D / CD3 FOR USE IN THE TREATMENT OF CANCER EA202092753A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842080P 2019-05-02 2019-05-02
PCT/IB2019/054033 WO2019220368A1 (en) 2018-05-16 2019-05-15 Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy

Publications (1)

Publication Number Publication Date
EA202092753A1 true EA202092753A1 (en) 2021-03-12

Family

ID=75262217

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202092754A EA202092754A1 (en) 2019-05-02 2019-05-15 METHODS FOR TREATING CANCER AND INCREASING THE EFFECTIVENESS OF THERAPEUTIC AGENTS REDIRECTING T-CELLS
EA202092753A EA202092753A1 (en) 2019-05-02 2019-05-15 BISPECIFIC ANTIBODIES TO BCMA / CD3 AND GPRDC5D / CD3 FOR USE IN THE TREATMENT OF CANCER

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202092754A EA202092754A1 (en) 2019-05-02 2019-05-15 METHODS FOR TREATING CANCER AND INCREASING THE EFFECTIVENESS OF THERAPEUTIC AGENTS REDIRECTING T-CELLS

Country Status (1)

Country Link
EA (2) EA202092754A1 (en)

Also Published As

Publication number Publication date
EA202092754A1 (en) 2021-04-06

Similar Documents

Publication Publication Date Title
JOP20200292A1 (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
PH12019502640A1 (en) Antibodies specific for flt3 and their uses
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
CR20200467A (en) Anti-cd25 for tumour specific cell depletion
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12019500550A1 (en) Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
MX2018010473A (en) Combination therapy with anti-cd73 antibodies.
JOP20200300A1 (en) Il-11ra antibodies
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
EA201691824A1 (en) ANTIBODIES AGAINST EGFRVIII AND THEIR APPLICATIONS
MX2021015888A (en) Fusion of an antibody binding cea and 4-1bbl.
MX2021000392A (en) Anti-mesothelin antibodies.
MX2021004732A (en) Heavy chain antibodies binding to cd38.
MX2019013753A (en) Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EA201992316A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSTIC OF PROSTATE CANCER
MX2021003673A (en) Anti-human vsig4 antibodies and uses thereof.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2019000963A (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion
EA202092753A1 (en) BISPECIFIC ANTIBODIES TO BCMA / CD3 AND GPRDC5D / CD3 FOR USE IN THE TREATMENT OF CANCER
MX2021001604A (en) Cancer treatment with an antibody.
EA202191605A1 (en) ANTIBODIES TO PERIOSTIN AND THEIR APPLICATION
EA202092947A1 (en) ANTI-PVRIG / ANTI-TIGIT BISPECIFIC ANTIBODIES AND METHODS OF THEIR APPLICATION
MX2022008745A (en) ANTI-NKp30 ANTIBODIES AND METHODS OF USE.